Panitumumab

A human monoclonal antibody produced in transgenic mice that attaches to the transmembrane epidermal growth factor (EGF) receptor. Panitumumab may inhibit autocrine EGF stimulation of tumor cells that express the EGF receptor, thereby inhibiting tumor cell proliferation.

Active ingredient of formulation:

Legal status:

Active moieties:

Also known as:

  • Vectibix

Medicine

Pregnancy category:

Marketed formulations:

Active moiety of formulation:

Active moiety of drug:

top ↑

Facts from the Community

From the BioVenturist base

Target/Biomolecule of Interest:

Indication or disease:

Disease Phase of development
View entire collection »

Technology involved:

View entire collection »

Sales:

Amount Year Area
  • 170,000,000
  • 2007
  • 39,000,000
  • 2006
View entire collection »

Developed by:

Brand Names:

  • Vectibix

Stage of development:

top ↑

We can also tell you Panitumumab is a…

If you know more about Panitumumab, you can add more facts here »

These people have edited this topic:

  • jg Metaweb Current Staff
  • tristan
Edit this topic
Edit and Show details

Add or delete facts, download data in JSON or RDF formats, and explore topic metadata.

Freebase Logo
What is Freebase?

Freebase is a huge collection of facts, built by people like you. Freebase connects facts in ways other sites can't, giving you new ways to explore millions of subjects.
You can help improve it!

Freebase Attribution

Freebase data is free for use under the CC-BY license.

Learn more about Freebase licensing and attribution »